{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+Malignancies%2C+Cancer&page=48", "query": { "condition": "Solid Tumor Malignancies, Cancer", "page": 48 }, "page_size": 10 }, "pagination": { "page": 48, "page_size": 10, "total_count": 5453, "total_pages": 546, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+Malignancies%2C+Cancer&page=49&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+Malignancies%2C+Cancer&page=47&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T04:22:51.528Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03156114", "title": "This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Ezabenlimab", "type": "DRUG" }, { "name": "BI 754111", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2017-06-13", "completion_date": "2023-06-06", "has_results": true, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-10-20T04:22:51.528Z", "location_count": 6, "location_summary": "Miami, Florida • Sarasota, Florida • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03156114" }, { "nct_id": "NCT01450384", "title": "Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2011-10", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2016-02-23", "last_synced_at": "2026-10-20T04:22:51.528Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01450384" }, { "nct_id": "NCT01673438", "title": "Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "aldoxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2012-07", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2022-02-10", "last_synced_at": "2026-10-20T04:22:51.528Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01673438" }, { "nct_id": "NCT02518958", "title": "A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Solid Tumor", "Lymphoma" ], "interventions": [ { "name": "RRx-001", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EpicentRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2015-07-21", "completion_date": "2016-09-12", "has_results": false, "last_update_posted_date": "2019-11-18", "last_synced_at": "2026-10-20T04:22:51.528Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02518958" }, { "nct_id": "NCT03953235", "title": "A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Pancreatic Cancer", "Solid Tumor", "Shared Neoantigen-Positive Solid Tumors" ], "interventions": [ { "name": "GRT-C903", "type": "BIOLOGICAL" }, { "name": "GRT-R904", "type": "BIOLOGICAL" }, { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gritstone bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2019-07-18", "completion_date": "2023-03-10", "has_results": false, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-10-20T04:22:51.528Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03953235" }, { "nct_id": "NCT03422874", "title": "Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Lymphoma" ], "interventions": [ { "name": "MLN9708", "type": "DRUG" }, { "name": "Nelfinavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-08", "completion_date": "2017-08-04", "has_results": false, "last_update_posted_date": "2018-02-06", "last_synced_at": "2026-10-20T04:22:51.528Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT03422874" }, { "nct_id": "NCT03330990", "title": "Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" }, { "name": "Midazolam Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2017-11-14", "completion_date": "2018-07-11", "has_results": false, "last_update_posted_date": "2018-08-21", "last_synced_at": "2026-10-20T04:22:51.528Z", "location_count": 3, "location_summary": "Denver, Colorado • Sarasota, Florida • Nashville, Tennessee", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03330990" }, { "nct_id": "NCT00607880", "title": "Study Comparing Two Types of Ports in Patients With Cancer Receiving Intravenous Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific", "Vascular Access Device Complications" ], "interventions": [ { "name": "vascular access device placement", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2004-06", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2014-05-09", "last_synced_at": "2026-10-20T04:22:51.528Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00607880" }, { "nct_id": "NCT00086762", "title": "Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Patients Who Are Undergoing Chemotherapy For Newly Diagnosed Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chemotherapy-induced Nausea and Vomiting", "Unspecified Adult Solid Tumor, Protocol Specific", "Breast Cancer", "Gastrointestinal Cancer", "Disease (or Disorder); Gynecological", "Prostate Cancer" ], "interventions": [ { "name": "MR Therapy", "type": "BEHAVIORAL" }, { "name": "Relaxing Music (RM) Therapy", "type": "BEHAVIORAL" }, { "name": "Standard Symptom Management", "type": "BEHAVIORAL" }, { "name": "Questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 474, "start_date": "2004-06", "completion_date": "2022-08-11", "has_results": false, "last_update_posted_date": "2022-09-01", "last_synced_at": "2026-10-20T04:22:51.528Z", "location_count": 9, "location_summary": "Wichita, Kansas • Ann Arbor, Michigan • Grand Rapids, Michigan + 6 more", "locations": [ { "city": "Wichita", "state": "Kansas" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Kalamazoo", "state": "Michigan" }, { "city": "Wynnewood", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00086762" }, { "nct_id": "NCT02243917", "title": "A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "CB-5083", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cleave Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2014-10-11", "completion_date": "2017-08-25", "has_results": false, "last_update_posted_date": "2018-02-27", "last_synced_at": "2026-10-20T04:22:51.528Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02243917" } ] }